secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001104659-23-087025
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics appoints Helen M. Boudreau, former Novartis CFO, to board
---------------------------------------------------------------------------

- Appointed effective August 2, 2023; term expires at 2024 annual meeting.
- Boudreau brings 30+ years experience; previously COO of Bill & Melinda Gates Medical Research Institute (2018-2019).
- Received initial stock option grant with Black-Scholes value of $350,000, vesting quarterly over three years.
- Will receive annual cash retainer of $50k for director service and $10k for audit committee (pro-rated 2023).
- Appointed to audit committee; currently serves on boards of Premier Inc., Shattuck Labs, and Rallybio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923087025/0001104659-23-087025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923087025/tm2322717d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-087025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer